可溶性LR11/SorLA水平在胆管癌和胰腺癌患者的胆汁中显著升高。
Levels of soluble LR11/SorLA are highly increased in the bile of patients with biliary tract and pancreatic cancers.
作者信息
Terai Kensuke, Jiang Meizi, Tokuyama Wataru, Murano Takeyoshi, Takada Nobuo, Fujimura Kengo, Ebinuma Hiroyuki, Kishimoto Toshihiko, Hiruta Nobuyuki, Schneider Wolfgang J, Bujo Hideaki
机构信息
Department of Clinical-Laboratory and Experimental-Research Medicine, Toho University Sakura Medical Center, Sakura, Japan; Department of Surgical Pathology, Toho University Sakura Medical Center, Sakura, Japan; Department of Biomolecular Science, Toho University Graduate School of Science, Funabashi, Japan.
Department of Clinical-Laboratory and Experimental-Research Medicine, Toho University Sakura Medical Center, Sakura, Japan.
出版信息
Clin Chim Acta. 2016 Jun 1;457:130-6. doi: 10.1016/j.cca.2016.04.010. Epub 2016 Apr 11.
BACKGROUND
The utility of molecules derived from cancer cells as biomarkers of the pathological status in biliary tract and pancreatic cancers is still limited. Soluble LDL receptor relative with 11 ligand-binding repeats (sLR11), a molecule released from immature cells, has been shown to be a circulating biomarker for early stage hematological malignancies.
METHODS
We have evaluated the pathological significance of bile sLR11 levels in 147 samples from 72 patients with biliary tract cancer (BTC), pancreatic cancer (PC), or benign diseases.
RESULTS
The bile sLR11 levels in the cancer patients were significantly increased compared with those in patients without cancer, independent of cytological detection of cancer cells in bile. The average bile sLR11 levels in cancer patients were significantly higher than in those with benign diseases, while levels of bile carbohydrate antigen 19-9 (CA19-9) and carcinoembryonic antigen (CEA) were not different. LR11 protein was found to be highly expressed in the BTC and PC cells. The LR11 transcript levels in cholangiocarcinoma and pancreatic cancer cell lines were sharply induced during proliferation and significantly increased under hypoxic conditions.
CONCLUSIONS
Therefore, sLR11 levels in bile may be indicative of cancer cell conditions and may serve as potential novel biomarker in patients with BTC and PC.
背景
源自癌细胞的分子作为胆管癌和胰腺癌病理状态生物标志物的效用仍然有限。可溶性低密度脂蛋白受体相关蛋白11（sLR11），一种从未成熟细胞释放的分子，已被证明是早期血液系统恶性肿瘤的循环生物标志物。
方法
我们评估了72例胆管癌（BTC）、胰腺癌（PC）或良性疾病患者的147份样本中胆汁sLR11水平的病理意义。
结果
与无癌患者相比，癌症患者胆汁中的sLR11水平显著升高，与胆汁中癌细胞的细胞学检测无关。癌症患者的平均胆汁sLR11水平显著高于良性疾病患者，而胆汁中糖类抗原19-9（CA19-9）和癌胚抗原（CEA）水平无差异。发现LR11蛋白在BTC和PC细胞中高表达。胆管癌细胞系和胰腺癌细胞系中的LR11转录水平在增殖过程中急剧诱导，并在缺氧条件下显著增加。
结论
因此，胆汁中的sLR11水平可能指示癌细胞状况，并可能作为BTC和PC患者潜在的新型生物标志物。
Zotero 插件